Key facts
- This page summarizes Douglas R. Baum's Form 4 filing for QSAM Biosciences, Inc..
- 2 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 13 Feb 2024, 16:00.
Douglas R. Baum - 06 Feb 2024 Form 4 Insider Report for QSAM Biosciences, Inc.
- Reporting relationship
- CEO/Director, Director
- Issuer ticker
- N/A
- Reported as of
- 06 Feb 2024
- Net transaction value
- -$1
- SEC form
- 4
- Accepted by SEC
- 13 Feb 2024, 16:00:24 UTC
- Prior SEC filing
- 23 Jun 2023
- Next SEC filing
- 02 May 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Douglas Baum
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Douglas R. Baum filed Form 4 for QSAM Biosciences, Inc. on 13 Feb 2024.
Change
- Previous filing in this sequence was filed on 23 Jun 2023.
- Current net transaction value: -$1.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
QSAM)
transaction
Common Stock
Conversion of derivative security
- Transaction value
- $3,906
- Shares
- +1,302
- Change %
- +0.35%
- Price
- $3.00
- Shares after
- 376,849
- Date
- 06 Feb 2024
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
QSAM)
transaction
Derivative
Series B Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- $3,907
- Shares
- Change %
- Price
- Shares after
- 0
- Date
- 06 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,302
- Exercise price
- $3.00
- Footnotes
- F1
QSAM)
holding
Derivative
Options to buy common stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 12,500
- Date
- 06 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,500
- Exercise price
- $10.00
- Footnotes
- F2
QSAM)
holding
Derivative
Options to buy common stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 200
- Date
- 06 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 200
- Exercise price
- $20.00
- Footnotes
- F3
QSAM)
holding
Derivative
Options to buy common stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 3,125
- Date
- 06 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,125
- Exercise price
- $14.40
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The Series B Convertible Preferred Stock was convertible into common stock at any time and had no expiration date. Pursuant to an Exchange Agreement signed by and between the Issuer and all Series B Preferred Stockholders as of 11/18/23, the Series B Preferred Stock was automatically exchangeable for common stock of the Issuer at a price of $3.00 per share upon the Issuer listing on Nasdaq or signing an agreement to be acquired.
Footnote F2
The option vests annually in two equal installments beginning on 3/3/2023.
Footnote F3
The option vested annually in two equal installments beginning on 1/14/2021.
Footnote F4
The option vested semi-annually in two equal installments beginning on 2/24/2022.